Jefferies Comments on LAVA Therapeutics and Seagen
By Senad Karaahmetovic Shares of Seagen (NASDAQ:SGEN) are down over 7% after Bloomberg News reported that talks with Merck (NYSE:MRK) are stalling. The two companies have not been...
Pre-Open Stock Movers: Farfetch Limited (NYSE:FTCH) 17% HIGHER; reported Q2 EPS of ($0.17), $0.13 better than the analyst estimate of ($0.30). Revenue for the quarter came in at...
The COVID-19 pandemic highlighted the importance of health care and the role biopharma companies play in drug and vaccine development. As a result, the sector grew tremendously...
Biotechnology stocks represent companies that research, develop or market healthcare-related therapies or products. They typically use living organisms, biological systems, or...
This stock market selloff has gone way too far—and it’s pumped up the dividend yields on some of our favorite high-yield closed-end funds (CEFs). That means it’s...
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The Company is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. The Company also develops a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate (ADC), technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The Company's approved medicines include ADCETRIS, PADCEV and TUKYSA.
|Average||183.43 (+33.19% Upside)|
|No. of Analysts||22|